The inactivation of p16 promotes the pathogenesis of many tumor types, including mesothelioma, breast cancer, pancreatic cancer, non-small cell lung cancer, esophageal cancer, and head and neck cancer [1,2,3,9]. Here, CDKN2A is linked to non-small cell lung carcinoma.